Sign In
Buy ELEV
$0.365
+0 (+0%)
At Close: Oct 22, 2025
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
01:57pm, Thursday, 12'th Jun 2025
NEW YORK , June 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of E
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
11:19am, Monday, 09'th Jun 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Elevation Oncology, Inc. (NASDAQ: ELEV) to Concentra Biosciences, LLC is fair to Elevatio
BOSTON , June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients a
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
07:30am, Thursday, 15'th May 2025
-- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 -- BOSTO
-- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON , April 25, 2025 /
-- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cel
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
02:05pm, Friday, 21'st Mar 2025
ELEV decides to stop developing its lead drug after disappointing data from an early-stage study evaluating its sole clinical-stage drug in gastric cancers.
Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%
11:46am, Thursday, 20'th Mar 2025
On Thursday, Elevation Oncology, Inc. ELEV elected to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC).
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
08:00am, Thursday, 20'th Mar 2025
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
04:30pm, Thursday, 06'th Mar 2025
-- Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ
Elevation Oncology to Participate in Upcoming Investor Conferences
07:30am, Tuesday, 25'th Feb 2025
BOSTON , Feb. 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
07:30am, Monday, 13'th Jan 2025
-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GE
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion
07:30am, Thursday, 12'th Dec 2024
Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 lev
